EUVIMEDEUVIMED entdecken
Korrektur

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma

New England Journal of Medicine · 09.04.2026 · 394 (14) · 1456-1456

DOI: 10.1056/nejmx250006 ↗

Kurz gefasst

Korrektur in der Zeitschrift New England Journal of Medicine, erschienen am 09.04.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

(2026). Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine, 394(14), 1456-1456. https://doi.org/10.1056/nejmx250006

Vancouver

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma. New England Journal of Medicine. 2026;394(14):1456-1456. doi:10.1056/nejmx250006

BibTeX
@article{euvimed2026,
  title = {Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma},
  journal = {New England Journal of Medicine},
  year = {2026},
  volume = {394},
  number = {14},
  pages = {1456--1456},
  doi = {10.1056/nejmx250006}
}
Kostenlos starten →